



Release No 17

29 March 2000

**On 28 March 2000 H. Lundbeck A/S's ordinary general meeting was held in Valby-Hallen**

On the general meeting the report from the Supervisory Board on the activities of the Company during the previous year was noted, the audited annual accounts and consolidated annual accounts were approved and discharge was granted to the Supervisory Board and the Board of Management.

The proposal from the Supervisory Board of a distribution of profit of DKK 2.25 per share was approved by the general assembly.

Arne V. Jensen (chairman), Lars Bruhn (deputy chairman), Flemming Lindeløv, Henrik Hertz, Sven Dyrlov Madsen and Bent Jakobsen were all re-elected as members of the Supervisory Board.

Deloitte & Touche, Statsautoriseret Revisionsaktieselskab and Grothen & Perregaard, Statsautoriseret Revisionsaktieselskab were re-elected as auditors.

The General Meeting empowered the Supervisory Board to purchase own shares, cf. section 48 in the (Danish) Companies Act. The authorisation will be in force until the next Ordinary General Meeting and will authorise purchase of own shares at a nominal value up to 10% of the company share capital, provided that the price of the shares at the time of purchase does not vary more than 10% from the latest official quotation at the Stock Exchange.

There were no further items on the agenda for the general meeting.

**The Supervisory Board**

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological diseases. It had consolidated net turnover of DKK 4.1 billion in 1999 and employs approximately 2,800 people.

*For further information please contact Senior Vice President, Hans Henrik Munch-Jensen, Corporate Communications & Investor Relations, phone +45 36 30 15 11, ext. 2660.*